Aethlon Medical Reports Key Financial Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Yahoo Finance
- Financial Improvement: As of March 31, 2026, Aethlon Medical reported approximately $5 million in cash and cash equivalents, which, while still limiting financial flexibility, reflects a significant reduction in net loss from $13.4 million to $7.2 million compared to the previous fiscal year, indicating effective cost control efforts.
- Operating Expense Reduction: The company achieved a 21.9% year-over-year decrease in operating expenses to approximately $7.3 million for fiscal 2026, a notable reduction that not only underscores the company's commitment to cost management but also potentially lays the groundwork for future financial stability.
- Clinical Research Progress: Aethlon Medical successfully completed enrollment and treatment of participants in Cohort 2 of its Australian oncology trial without safety concerns, which lays a foundation for further applications of its Hemopurifier platform, although it remains in the early stages of clinical trials.
- Successful Fundraising: The company raised approximately $1.85 million in net proceeds through its at-the-market program, which not only strengthens its balance sheet but also provides essential support for future research and market expansion initiatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AEMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AEMD
About AEMD
Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aethlon Medical Reports Key Financial Highlights
- Financial Improvement: As of March 31, 2026, Aethlon Medical reported approximately $5 million in cash and cash equivalents, which, while still limiting financial flexibility, reflects a significant reduction in net loss from $13.4 million to $7.2 million compared to the previous fiscal year, indicating effective cost control efforts.
- Operating Expense Reduction: The company achieved a 21.9% year-over-year decrease in operating expenses to approximately $7.3 million for fiscal 2026, a notable reduction that not only underscores the company's commitment to cost management but also potentially lays the groundwork for future financial stability.
- Clinical Research Progress: Aethlon Medical successfully completed enrollment and treatment of participants in Cohort 2 of its Australian oncology trial without safety concerns, which lays a foundation for further applications of its Hemopurifier platform, although it remains in the early stages of clinical trials.
- Successful Fundraising: The company raised approximately $1.85 million in net proceeds through its at-the-market program, which not only strengthens its balance sheet but also provides essential support for future research and market expansion initiatives.
See More
Aethlon Medical Q4 2026 Earnings Call Insights
- Financial Improvement: As of March 31, 2026, Aethlon Medical reported a 21.9% year-over-year decline in operating expenses to approximately $7.3 million, primarily due to a $1.1 million reduction in payroll and related expenses, a $500,000 decrease in general and administrative costs, and a $400,000 cut in professional fees, effectively controlling costs and improving financial health.
- Clinical Trial Progress: Enrollment and treatment of participants in the second cohort of the Australian oncology trial have been completed, with the first participant in the third cohort enrolled and receiving three Hemopurifier treatments without device deficiencies or complications, indicating safety and efficacy in the trial.
- Successful Fundraising: Subsequent to the fiscal year-end, the company raised approximately $1.85 million in net proceeds through its at-the-market program, further strengthening its balance sheet and ensuring funding for future research and operations.
- Future Development Strategy: Management reiterated its commitment to advancing the Hemopurifier platform while maintaining disciplined cost control and careful capital management, with plans for formal statistical analyses in future trials to evaluate the effects of different dosing regimens, ensuring the product's market competitiveness.
See More
Aethlon Medical Reports FY 2026 Financial Results
- Reduced Net Loss: Aethlon Medical reported a net loss of $7.2 million for the fiscal year ending March 31, 2026, a significant decrease from the $13.4 million loss in FY 2025, indicating progress in cost control and operational optimization.
- Cash Position: As of March 31, 2026, the company had approximately $5.0 million in cash and cash equivalents, providing essential funding for ongoing clinical and research activities, thereby ensuring operational stability for the upcoming year.
- Financial Transparency: The financial report includes consolidated balance sheets and statements of operations for March 31, 2026, and 2025, enhancing investor understanding and confidence in the company's financial health.
- Market Performance Analysis: Following the release of Aethlon Medical's financial data, the market maintains a cautiously optimistic outlook on its future development, despite ongoing challenges from industry competition and market volatility.
See More
Aethlon (AEMD) Q4 2026 Earnings Transcript
See More
Aethlon Medical Advances Australian Oncology Study to Final Cohort
- Clinical Progress: Aethlon Medical has successfully advanced to the third dosing cohort of its Australian oncology study, completing participant enrollment and treatment in Cohort 2, with an independent Data Safety Monitoring Board confirming no safety concerns and recommending progression to the final phase, which is expected to provide crucial data for optimizing treatment regimens.
- Intellectual Property Expansion: During fiscal 2026, the company strengthened its Hemopurifier platform's intellectual property portfolio by securing patents in the U.S. and Europe covering two potential applications for coronavirus-related conditions, extending protection into the 2040s and further solidifying its market position.
- Financial Performance: As of March 31, 2026, the company reported approximately $5 million in cash and cash equivalents, with operating expenses declining by 21.9% year-over-year to $7.3 million, reflecting ongoing expense management and operational efficiency, while the operating loss decreased from $9.3 million to $7.3 million, indicating improved financial health.
- Future Outlook: The company is evaluating the compatibility of the Hemopurifier with a simplified blood treatment system developed by Stavro Medical, with initial testing completed, which could expand treatment settings for the Hemopurifier and enhance accessibility and scalability of treatment, further driving business growth.
See More
Aethlon Medical Advances Australian Oncology Study into Final Cohort
- Clinical Progress: Aethlon Medical has successfully advanced into the third dosing cohort of its Australian oncology study, marking a key clinical milestone that is expected to provide important data for future treatment strategies.
- Participant Treatment: The first participant at Royal North Shore Hospital completed three Hemopurifier treatments, demonstrating ongoing enrollment momentum and execution strength, further propelling the clinical trial's progress.
- Intellectual Property Expansion: The company strengthened its Hemopurifier platform's intellectual property portfolio by securing patents in the U.S. and Europe for potential applications related to coronavirus diseases, extending patent protection into the 2040s and enhancing long-term platform value.
- Financial Performance: As of March 31, 2026, the company had approximately $5 million in cash and cash equivalents, with operating expenses declining 21.9% year-over-year to $7.3 million, reflecting ongoing expense control and operational efficiency.
See More
Aethlon Medical Reports Key Financial Highlights
- Financial Improvement: As of March 31, 2026, Aethlon Medical reported approximately $5 million in cash and cash equivalents, which, while still limiting financial flexibility, reflects a significant reduction in net loss from $13.4 million to $7.2 million compared to the previous fiscal year, indicating effective cost control efforts.
- Operating Expense Reduction: The company achieved a 21.9% year-over-year decrease in operating expenses to approximately $7.3 million for fiscal 2026, a notable reduction that not only underscores the company's commitment to cost management but also potentially lays the groundwork for future financial stability.
- Clinical Research Progress: Aethlon Medical successfully completed enrollment and treatment of participants in Cohort 2 of its Australian oncology trial without safety concerns, which lays a foundation for further applications of its Hemopurifier platform, although it remains in the early stages of clinical trials.
- Successful Fundraising: The company raised approximately $1.85 million in net proceeds through its at-the-market program, which not only strengthens its balance sheet but also provides essential support for future research and market expansion initiatives.
See More
Aethlon Medical Q4 2026 Earnings Call Insights
- Financial Improvement: As of March 31, 2026, Aethlon Medical reported a 21.9% year-over-year decline in operating expenses to approximately $7.3 million, primarily due to a $1.1 million reduction in payroll and related expenses, a $500,000 decrease in general and administrative costs, and a $400,000 cut in professional fees, effectively controlling costs and improving financial health.
- Clinical Trial Progress: Enrollment and treatment of participants in the second cohort of the Australian oncology trial have been completed, with the first participant in the third cohort enrolled and receiving three Hemopurifier treatments without device deficiencies or complications, indicating safety and efficacy in the trial.
- Successful Fundraising: Subsequent to the fiscal year-end, the company raised approximately $1.85 million in net proceeds through its at-the-market program, further strengthening its balance sheet and ensuring funding for future research and operations.
- Future Development Strategy: Management reiterated its commitment to advancing the Hemopurifier platform while maintaining disciplined cost control and careful capital management, with plans for formal statistical analyses in future trials to evaluate the effects of different dosing regimens, ensuring the product's market competitiveness.
See More
Aethlon Medical Reports FY 2026 Financial Results
- Reduced Net Loss: Aethlon Medical reported a net loss of $7.2 million for the fiscal year ending March 31, 2026, a significant decrease from the $13.4 million loss in FY 2025, indicating progress in cost control and operational optimization.
- Cash Position: As of March 31, 2026, the company had approximately $5.0 million in cash and cash equivalents, providing essential funding for ongoing clinical and research activities, thereby ensuring operational stability for the upcoming year.
- Financial Transparency: The financial report includes consolidated balance sheets and statements of operations for March 31, 2026, and 2025, enhancing investor understanding and confidence in the company's financial health.
- Market Performance Analysis: Following the release of Aethlon Medical's financial data, the market maintains a cautiously optimistic outlook on its future development, despite ongoing challenges from industry competition and market volatility.
See More
Aethlon (AEMD) Q4 2026 Earnings Transcript
See More
Aethlon Medical Advances Australian Oncology Study to Final Cohort
- Clinical Progress: Aethlon Medical has successfully advanced to the third dosing cohort of its Australian oncology study, completing participant enrollment and treatment in Cohort 2, with an independent Data Safety Monitoring Board confirming no safety concerns and recommending progression to the final phase, which is expected to provide crucial data for optimizing treatment regimens.
- Intellectual Property Expansion: During fiscal 2026, the company strengthened its Hemopurifier platform's intellectual property portfolio by securing patents in the U.S. and Europe covering two potential applications for coronavirus-related conditions, extending protection into the 2040s and further solidifying its market position.
- Financial Performance: As of March 31, 2026, the company reported approximately $5 million in cash and cash equivalents, with operating expenses declining by 21.9% year-over-year to $7.3 million, reflecting ongoing expense management and operational efficiency, while the operating loss decreased from $9.3 million to $7.3 million, indicating improved financial health.
- Future Outlook: The company is evaluating the compatibility of the Hemopurifier with a simplified blood treatment system developed by Stavro Medical, with initial testing completed, which could expand treatment settings for the Hemopurifier and enhance accessibility and scalability of treatment, further driving business growth.
See More
Aethlon Medical Advances Australian Oncology Study into Final Cohort
- Clinical Progress: Aethlon Medical has successfully advanced into the third dosing cohort of its Australian oncology study, marking a key clinical milestone that is expected to provide important data for future treatment strategies.
- Participant Treatment: The first participant at Royal North Shore Hospital completed three Hemopurifier treatments, demonstrating ongoing enrollment momentum and execution strength, further propelling the clinical trial's progress.
- Intellectual Property Expansion: The company strengthened its Hemopurifier platform's intellectual property portfolio by securing patents in the U.S. and Europe for potential applications related to coronavirus diseases, extending patent protection into the 2040s and enhancing long-term platform value.
- Financial Performance: As of March 31, 2026, the company had approximately $5 million in cash and cash equivalents, with operating expenses declining 21.9% year-over-year to $7.3 million, reflecting ongoing expense control and operational efficiency.
See More
